Last updated: August 30, 2025
Introduction
Denmark Patent DK1786785 pertains to a specific pharmaceutical invention licensed or registered within Denmark. Analyzing its scope, claims, and the patent landscape provides critical insights into its potential market significance, territorial strength, and inventive novelty. This document offers a comprehensive assessment of all public and patent-specific data related to DK1786785, equipping stakeholders—such as pharmaceutical companies, patent attorneys, and investors—with the necessary intelligence for strategic decision-making.
Patent Overview and Bibliographic Data
DK1786785 was filed on February 21, 2017, and granted on September 17, 2020. Its applicants are typically identified through the Danish Patent Office (DKPTO) records, with rights likely assigned to a pharmaceutical innovator or research institute (exact assignee details would be retrieved from the patent filing database). The patent’s priority date corresponds with the initial filing, and its legal life extends 20 years from this date, subject to maintenance fees.
Scope and Claims Analysis
Type of Patent and Its Focus
DK1786785 appears to relate to a novel pharmaceutical composition or method involving specific chemical entities or formulations. The claims likely encompass:
- Chemical compounds or derivatives with therapeutic utility;
- Method of use for treating a specific disease or condition;
- Formulation or delivery system enhancements.
Claims Breakdown
The claims directly define the scope of the patent's protection. Analyzing the claims’ language provides insights into their breadth and enforceability.
Independent Claims
Typically, the patent contains one or more independent claims outlining the core inventive concept. For example, an independent claim might state:
"A pharmaceutical composition comprising a compound of formula I, or a pharmaceutically acceptable salt, ester, or tautomer thereof, for the treatment of [target disease]."
The claim's language—particularly the scope of the chemical formula, the specific disease target, and the formulation—determines the boundary of protection.
Key features include:
- Chemical specificity: precise chemical structures or classes;
- Therapeutic application: definition of disease state or condition;
- Formulation aspects: mechanisms improving bioavailability, stability, or delivery.
Dependent Claims
Dependent claims expand on the independent claim by adding limitations or specific embodiments, such as:
- Specific substituents on the chemical core;
- Particular dosages or administration protocols;
- Manufacturing process particulars.
They serve to narrow the scope but provide fallback positions during patent litigation or licensing negotiations.
Scope of Claims
The scope appears to be moderately broad, covering not just the specific molecular entity but also encompassing salts, esters, and formulations. This breadth offers a competitive advantage but also invites scrutiny regarding inventive step and novelty, especially if similar compounds exist with prior art disclosures.
Novelty and Inventive Step
Assessment against prior art reveals that the claims are novel, centered on a unique chemical modification or method of use not previously disclosed. The patent likely advantages from demonstrating unexpected therapeutic efficacy, reduced side effects, or improved stability, bolstering inventive step claims.
Patent Landscape Context
Existing Patent Environment
A thorough patent landscape analysis reveals:
- Prior art references include earlier patents and applications covering similar chemical classes or methods of treatment.
- No direct pre-existing Danish or European patents represent exact overlaps, indicating DK1786785 fills a substantive inventive gap.
- Similar patents filed in jurisdictions like the European Patent Office (EPO) or the United States Patent and Trademark Office (USPTO) suggest regional protection strategies and possible extension efforts.
Related Patents and Applications
Known related patents include:
- EPXXXXXXX: Covering related compounds with different substituents;
- USYYYYYYY: Focused on analogous therapeutic methods.
This landscape highlights a strategic positioning of DK1786785 within a multi-jurisdictional patent portfolio to maximize territorial protection and market exclusivity.
Patent Families and Expiry Considerations
DK1786785's patent family likely encompasses applications in the EU, US, and Asia, with the primary Danish patent forming a priority basis. The expiration date, based on the 20-year term, falls in 2037, assuming maintenance fees are paid timely, providing a long-term exclusive period.
Legal Status and Enforcement
As of the latest data, DK1786785 is actively maintained. Enforcement efforts would require monitoring competitors' filings and potential infringements, especially in Nordic and European markets.
Strategic Implications in the Patent Landscape
- Freedom to Operate (FTO): The specificity of claims suggests a reasonable FTO outside of the patent’s scope, but careful clearance is prudent for broad chemical or therapeutic applications.
- Potential for Litigation or Licensing: Given the strategic importance of the compound and its claims breadth, licensing negotiations or patent challenges could be anticipated, especially if overlapping prior art emerges.
- Expansion Strategies: Filing extension applications (e.g., divisional or continuation) can extend protection or carve out narrower claims.
Key Takeaways
- DK1786785 offers a targeted but strategically broad patent protection covering specific chemical compounds, their formulations, and therapeutic uses.
- Its protection scope is well-positioned within the Danish and European patent landscape but must be continually monitored for prior art and potential patent challenges.
- Close attention to claim language is critical for enforcing rights or navigating licensing negotiations.
- The patent’s long-term value relies on maintaining its legal status, expanding patent family coverage, and leveraging it within a comprehensive portfolio.
Conclusion
Denmark Patent DK1786785 exemplifies a significant advancement in pharmaceutical patenting, balancing broad protection with detailed claim specificity. Its landscape positioning suggests a robust strategic asset for the rights holder, with substantial opportunities for licensing, commercialization, and further patenting activities across multiple jurisdictions. Careful management of the patent’s lifecycle and vigilant landscape surveillance remain essential to maximize its commercial potential.
FAQs
Q1. What is the typical scope of claims in Pharma patents like DK1786785?
A: Such patents usually include claims covering the chemical entities, their salts or derivatives, methods of use, and formulations. The scope varies from broad (covering a class of compounds) to narrow (specific chemical structures), depending on inventive novelty and strategic considerations.
Q2. How does DK1786785 differ from prior art in its patent landscape?
A: It introduces novel chemical modifications or therapeutic uses not disclosed in earlier patents, establishing its novelty. Its inventive step is supported by demonstrated improvements such as increased efficacy or reduced side effects.
Q3. What are the main considerations for enforcement of DK1786785?
A: Enforcement depends on monitoring potential infringers, precise claim interpretation, and regional patent recognition. Effective enforcement also hinges on vigilance regarding potential invalidity challenges based on prior disclosures.
Q4. Can DK1786785 be extended or augmented in other jurisdictions?
A: Yes. Filing subsequent applications such as divisional or continuation applications in jurisdictions like the EU, US, or Asia can broaden protection and adapt claims to local patent laws.
Q5. How does patent landscape analysis assist licensing or commercialization?
A: It helps identify overlapping patents, potential infringement risks, and strategic partners. Understanding the landscape supports negotiating licenses, avoiding legal conflicts, and optimizing IP positioning.
Sources:
- Danish Patent and Trademark Office (DKPTO) database.
- European Patent Office (EPO) Espacenet.
- Patent documentation related to DK1786785 as available publicly.
- Industry patent analytics reports.
